This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

andy, totally agree with u, it is exactly I mean in my last post. I desided to hold it coz I know it is a good company, and have a bright future. MM is now playing game, but I am not joining in and not panic to sell as well, just hold my share. As righ now, I am out of bullet to buy, so I will wait until the price stable.

Guys I've gone back through the postings and want to try a give everyone some positive thoughts. So I've reposted this. Note the date, it was less than a month ago with a price of 275p. With the exception of the presentation nothing has changed. Andy called this one right warning us but none of us listened. We all got carried away and lost the plot. EK called it right as well. When I took the time to be dispassionate, it became obvious that this was a screaming short. Should the price rise again on nothing substantial then it will remain so. Don't panic and have patience, our day will come and plan you exit point.


goldfinger - 19 Apr'05 - 00:17 - 1302 of 1570

The last but one Insinger note, we know they have now updated to 275p.


Insinger de Beaufort 131 Finsbury Pavement
Tel +44 (0) 20 7190 7000 London
www.insinger.com EC2A 1NT
UK Equity Research 22 February 2005
Trading View
Independent Banking
Source: Insinger de Beaufort, Bloomberg

Accelerating development pipeline

Significant commercial potential: MMI is an emerging biotechnology company
focused in cancer and infectious diseases, both areas of significant commercial
potential. MMIs strategy is to develop drugs to Phase II clinical trial stage and then
commercialise via out-licencing agreements with pharmaceutical companies. Thin
pipelines and patent expiries have acted as a catalyst for a large number of deals
with small cap biotechs such as MMI, even for products which are relatively early
stage. For example a deal with Oxxon Therapeutics could potentially be worth up to
44m in up-front and milestone payments in order to access Xenovas early stage
cancer DISC HSV vector technology. It is also interesting to note recent benchmark
deals for pre clinical early stage compounds with promise - Novartis paid c.$157m to
Xenon and J&J is paying up to $295m in a deal excluding royalties to Arena.
MMI has four R&D divisions:
a) Oncosense (wholly owned) - technology based around the precious metal
ruthenium which is potentially up to 15 times more efficacious than the
most potent platinum anticancer drug.
b) Genvax (JV) - developing DNA vaccines for cancer with Southampton
University/Cancer Research UK Leukaemia Research Fund
c) Viratis (JV) - viral infections with Kings College London
d) Endozyme (wholly owned) - drug resistant Infections working with
Cambridge University/Novartis
MMI also provides technical services to UK academic and commercial institutions
which apart from generating revenues, also provides a stream of potential in -
licensing opportunities.
Tight cost control: Given a current cash balance of 2.6m, MMI has enough cash to
last until Q1 06. Whilst it would not be prudent to discount a future fund raising,
additional cash inflows may come from licensing deals. Furthermore

I still wonder if MMI are pandering to a big pharma regarding Ru.
Why say you are going to clinic within 3 months (at AGM in OCT, DB said RU in clinic late 2004) and then 5 months later you are still not there.
Nothing changed during that time so you have to wonder why.
My guess would be a big pharma stipulated extra tests and have all but agreed a deal pending these further tests.

Put this against a backdrop of late stage failures and setbacks for the big pharmas pipelines and it all seems feasible (IMHO).

These are just my musings based on second guessing and trying to read between the lines of DB's dialogue.

I was wondering why they bought Dr H in at such a late stage in developments it must have been on the insistance of DB that nothing was left to chance when there was a deal in the offing.

Mitzy

When do you think we'll hear some news? Probable a few weeks away yet. Does DB check out the sp regularly. If so he'll know what's going on and hopefully do something about it.

MS
PS Where's GF today?

GF went to bed and will be back at 5 for the election news.

Dont forget DB and MM (His wife) are by far the largest shareholders and have more to lose than most.
There is not much he can do to control the SP and would be very surprised if he rushed out an RNS for that reason.
The SP will find its true level based on supply, demand and MM manipulation.

I wish I knew mickey.. the Ru clinical trials news is 5 months late as Pete has already mentioned.

Does anyone know what the share holding distribution is ie who owns what.

MS

50,850,000 - Shares in Issue

12,495,375 - David Best
6,637,375 - Margaret Mitchell
2,409,142 - 26 Nov 03 Placing
1,841,858 - Institution
3,351,000 - 28 Oct 04 placing
3,205,000 - Universities Superannuation
6,500,000 - Prudential
-----------
36,439,750
-----------

14,410,250 - Unaccounted

Holdings below 3% not reported.

Thanks pete nice one.

MS

Gone a bit quiet on this thread...do you think the MMG share price has bottomed out?

I am hoping so - as I have just bought 100% into the share competition - as well as my real shares - which are considerably underwater. Nevertheless I still think great products, great potential - if only they can get the commercials and the Sales & Marketing right.

Has the evil one lost interest in this share yet ?
Baza

Great move up this morning after yesterdays tip.Not sure about the 300p target though.

Who knows. There's been no news to drive the price up and EK's short is still in place, so your guess is as good as mine.

MS

morning all, great to see this one on the move and hopefully all shorters closing positions-EK may say something in his next diary mention (fri??) if anyone has access. Could you let me know who was tipping this yesterday? thanks. tau

I understand Zac Mir(is that the right spelling) tipped them to go up yesterday although I cannot confirm that he said they would return to 300p.

Well I am with Zac Mir - however you spell his name. - but would like to see his justification and who his audience is?
Thanks
Baza

Zak Mir has his own web site Zaks-TA.com which is pure technical analysis. He also works with Tom Winnifrith and Simon Cawkwell on t1ps.com. He is highly regarded and did work for Shares Mag. He resigned to set up on his own. I can't find any postings he's made about MMG but if Zak said it then you're a brave man to argue against him. EK is still short but could well reverse his position.

MS

I can't help thinking that despite Zac's tip and the rally based on technicals that this stock is highly vulnerable without news or adequate PR. I would love to see it rise to 300p and beyond but I think you're brave stepping in now. Looks very cheap but still shakey & weak to me.